Login to Your Account



Opko bid in GHD skewed by outlier; analysis to tell true result

By Randy Osborne
Staff Writer

Friday, December 30, 2016

A weight-losing outlier in the phase III trial's placebo group "should have been picked up earlier or should have been thrown out before we unblinded," Opko Health Inc.'s vice president, Steven Rubin, told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription